A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

C. Garufi, E. Bria, B. Vanni, A. M R Zappalà, I. Sperduti, E. Terzoli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients. The aim of this study was to determine the tolerability and activity of CPT-11 plus chronomodulated infusion of L-OHP, 5-FU and FA in ACRC patients. A total of 35 patients (91% pretreated, 77% with CPT-11, 54% with L-OHP, 42% with both) were treated every 3 weeks with CPT-11, 180 mg m-2 day 1 i.v., plus L-OHP, 20 mg m-2 day-1, 5-FU, 700 mg m-2 day -1 and FA, 150 mg m-2 day-1, all three drugs from day 2 to day 5 by chronomodulated infusion. The patients' (pt) data were as follows: male/female 21/14; median age 58 years (range: 38-70); PS 0: 26 pts (74%), PS 1: 8 pts (23%), PS 2: 1 pt (3%); primary tumour colon/rectum 26/9; involved organs: 1, 14 pts (40%); 2, 17 pts (48%); ≥3: 4 pts (11%); previous chemotherapy lines 1: 12 pts (34%), 2: 10 pts (28%), ≥3: 10 pts (28%). A total of 221 courses (c) were performed; no grade 4 toxicity was observed with only one grade 3 (G3) neutropenia and thrombocytopenia (3%) in one out of 221 courses (

Original languageEnglish
Pages (from-to)1870-1875
Number of pages6
JournalBritish Journal of Cancer
Volume89
Issue number10
DOIs
Publication statusPublished - Nov 17 2003

Fingerprint

oxaliplatin
irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Neutropenia
Rectum
Colon
Drug Therapy

Keywords

  • Chronotherapy
  • Colorectal cancer
  • Irinotecan
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. / Garufi, C.; Bria, E.; Vanni, B.; Zappalà, A. M R; Sperduti, I.; Terzoli, E.

In: British Journal of Cancer, Vol. 89, No. 10, 17.11.2003, p. 1870-1875.

Research output: Contribution to journalArticle

Garufi, C. ; Bria, E. ; Vanni, B. ; Zappalà, A. M R ; Sperduti, I. ; Terzoli, E. / A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. In: British Journal of Cancer. 2003 ; Vol. 89, No. 10. pp. 1870-1875.
@article{4b65ac540f65450c9d93db206ba068c8,
title = "A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients",
abstract = "The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients. The aim of this study was to determine the tolerability and activity of CPT-11 plus chronomodulated infusion of L-OHP, 5-FU and FA in ACRC patients. A total of 35 patients (91{\%} pretreated, 77{\%} with CPT-11, 54{\%} with L-OHP, 42{\%} with both) were treated every 3 weeks with CPT-11, 180 mg m-2 day 1 i.v., plus L-OHP, 20 mg m-2 day-1, 5-FU, 700 mg m-2 day -1 and FA, 150 mg m-2 day-1, all three drugs from day 2 to day 5 by chronomodulated infusion. The patients' (pt) data were as follows: male/female 21/14; median age 58 years (range: 38-70); PS 0: 26 pts (74{\%}), PS 1: 8 pts (23{\%}), PS 2: 1 pt (3{\%}); primary tumour colon/rectum 26/9; involved organs: 1, 14 pts (40{\%}); 2, 17 pts (48{\%}); ≥3: 4 pts (11{\%}); previous chemotherapy lines 1: 12 pts (34{\%}), 2: 10 pts (28{\%}), ≥3: 10 pts (28{\%}). A total of 221 courses (c) were performed; no grade 4 toxicity was observed with only one grade 3 (G3) neutropenia and thrombocytopenia (3{\%}) in one out of 221 courses (",
keywords = "Chronotherapy, Colorectal cancer, Irinotecan, Oxaliplatin",
author = "C. Garufi and E. Bria and B. Vanni and Zappal{\`a}, {A. M R} and I. Sperduti and E. Terzoli",
year = "2003",
month = "11",
day = "17",
doi = "10.1038/sj.bjc.6601382",
language = "English",
volume = "89",
pages = "1870--1875",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

AU - Garufi, C.

AU - Bria, E.

AU - Vanni, B.

AU - Zappalà, A. M R

AU - Sperduti, I.

AU - Terzoli, E.

PY - 2003/11/17

Y1 - 2003/11/17

N2 - The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients. The aim of this study was to determine the tolerability and activity of CPT-11 plus chronomodulated infusion of L-OHP, 5-FU and FA in ACRC patients. A total of 35 patients (91% pretreated, 77% with CPT-11, 54% with L-OHP, 42% with both) were treated every 3 weeks with CPT-11, 180 mg m-2 day 1 i.v., plus L-OHP, 20 mg m-2 day-1, 5-FU, 700 mg m-2 day -1 and FA, 150 mg m-2 day-1, all three drugs from day 2 to day 5 by chronomodulated infusion. The patients' (pt) data were as follows: male/female 21/14; median age 58 years (range: 38-70); PS 0: 26 pts (74%), PS 1: 8 pts (23%), PS 2: 1 pt (3%); primary tumour colon/rectum 26/9; involved organs: 1, 14 pts (40%); 2, 17 pts (48%); ≥3: 4 pts (11%); previous chemotherapy lines 1: 12 pts (34%), 2: 10 pts (28%), ≥3: 10 pts (28%). A total of 221 courses (c) were performed; no grade 4 toxicity was observed with only one grade 3 (G3) neutropenia and thrombocytopenia (3%) in one out of 221 courses (

AB - The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients. The aim of this study was to determine the tolerability and activity of CPT-11 plus chronomodulated infusion of L-OHP, 5-FU and FA in ACRC patients. A total of 35 patients (91% pretreated, 77% with CPT-11, 54% with L-OHP, 42% with both) were treated every 3 weeks with CPT-11, 180 mg m-2 day 1 i.v., plus L-OHP, 20 mg m-2 day-1, 5-FU, 700 mg m-2 day -1 and FA, 150 mg m-2 day-1, all three drugs from day 2 to day 5 by chronomodulated infusion. The patients' (pt) data were as follows: male/female 21/14; median age 58 years (range: 38-70); PS 0: 26 pts (74%), PS 1: 8 pts (23%), PS 2: 1 pt (3%); primary tumour colon/rectum 26/9; involved organs: 1, 14 pts (40%); 2, 17 pts (48%); ≥3: 4 pts (11%); previous chemotherapy lines 1: 12 pts (34%), 2: 10 pts (28%), ≥3: 10 pts (28%). A total of 221 courses (c) were performed; no grade 4 toxicity was observed with only one grade 3 (G3) neutropenia and thrombocytopenia (3%) in one out of 221 courses (

KW - Chronotherapy

KW - Colorectal cancer

KW - Irinotecan

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=0348013441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348013441&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601382

DO - 10.1038/sj.bjc.6601382

M3 - Article

VL - 89

SP - 1870

EP - 1875

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -